Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;101:e205-e206

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosen, S. D.
Right arrow Articles by Czernin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosen, S. D.
Right arrow Articles by Czernin, J.
Related Collections
Right arrow Nuclear cardiology and PET
Right arrow Coronary circulation
Right arrow Endothelium/vascular type/nitric oxide

(Circulation. 2000;101:e205.)
© 2000 American Heart Association, Inc.


Circulation Electronic Pages

Endothelium-Dependent and -Independent Perfusion Reserve and the Effect of L-Arginine on Myocardial Perfusion in Patients With Syndrome X

Stuart D. Rosen, MA, MD, MRCP, FESC, FACC; Paolo G. Camici, MD, FRCP, FESC, FACC

MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, SDandA.Rosen@btinternet.com


*    Introduction
up arrowTop
*Introduction
down arrowReferences
down arrowIntroduction 
down arrowReferences 
 
To the Editor:

We read the recent article by Bøttcher et al1 with interest. Unfortunately, the authors do not discuss their findings in the light of a previous study by our group.2 This study is quite relevant to their work and was published in Circulation 5 years ago. In our experiment, we also used positron emission tomography to measure myocardial blood flow (MBF) at rest and after the administration of intravenous dipyridamole in patients with syndrome X (n=29) and in a substantial control group (n=20). Our principal finding was that no significant differences existed between patients and controls with respect to myocardial blood flow (Figure 1Down). With a broader range of controls, Bøttcher et al’s corresponding figure (Figure 2Down) would probably not be distinguishable from ours.



View larger version (25K):
[in this window]
[in a new window]
 
Figure 1. Graph shows myocardial blood flow at rest and after dipyridamole (Dip.) in syndrome X patients and normal control subjects. Reproduced with permission from Reference 2.



View larger version (28K):
[in this window]
[in a new window]
 
Figure 2. Resting myocardial blood flow in mL · g-1 · min-1 and hyperemic myocardial blood flow after infusion of dipyridamole (DIP) 0.56 mL · kg-1 · min-1 in patients with syndrome X (n=25) and normal controls (group A, age-matched [n=15]; group B, young [n=15]). *P<0.05 rest vs DIP; +P<0.05 vs control group A; ¤P<0.05 vs control group B. Reproduced with permission from Reference 1.

Although Bøttcher et al’s data are quite consistent with ours in a number of respects, their interpretation of the data is perplexing. For example, on 2 occasions in the article, they state that basal MBF was elevated; however, their table shows that no significant difference was found for basal MBF between their patients and the age-matched controls. It is then suggested that an accumulation of adenosine in the extravascular component (caused by patchily distributed prearteriolar constriction or inadequate dilatation) offers a unifying hypothesis for the generation of pain and for the ECG changes observed. In our study, there were no demonstrable relationships among MBF, chest pain, or the dipyridamole-induced ECG changes; the clinical use of aminophylline has been, for the most part, disappointing.

Although ultimately the authors offer "differences in patients’ characteristics" and the "heterogeneous nature of the disorder" as an explanation for discrepancies with other studies in the literature, more fruitful avenues for research on this topic, other than MBF, deserve attention (for example, Cannon’s3 recent work).


*    References
up arrowTop
up arrowIntroduction
*References
down arrowIntroduction 
down arrowReferences 
 
1. Bøttcher M, Bøtker HE, Sonne H, et al. Endothelium-dependent and -independent perfusion reserve and the effect of L-arginine on myocardial perfusion in patients with syndrome X. Circulation. 1999;99:1795–1801.[Abstract/Free Full Text]

2. Rosen SD, Uren NG, Kaski J-C, et al. Coronary vasodilator reserve, pain perception, and gender in patients with syndrome X. Circulation.. 1994;90:50–60.[Abstract/Free Full Text]

3. Cannon RO III. The sensitive heart: a syndrome of abnormal cardiac pain perception. J Am Med Assoc. 1995;273:883–887.zkey[Abstract/Free Full Text]

Response

Morten Bøttcher, MD; Hans Erik Bøtker, MD, PhD; Helle Sonne, MD; Torsten Toftegaard Nielsen, MD; Johannes Czernin, MD

Department of Cardiology B, University Hospital of Aarhus (SKS), DK-8200 Aarhus N, Denmark


*    Introduction 
up arrowTop
up arrowIntroduction
up arrowReferences
*Introduction 
down arrowReferences 
 
We thank Drs Rosen and Camici for their interest in our article. They raise several issues regarding the interpretation of our findings.

We acknowledge that a reference to their previous article could have been made. An important difference exists between the control group used in their study and the one in our study. Rosen et al’s population consisted of patients undergoing angiography due to atypical chest pain symptoms. The angiography and the ensuing exercise test were normal. In contrast, our control group consisted of healthy subjects with no chest pain symptoms. The difference is nicely illustrated in the figures provided by Rosen and Camici. In the control group of Rosen et al’s study, several controls have extremely low hyperemic flow values. This was not the case in our study. We hypothesize that some of the controls in Rosen et al’s study may have subdetectable disease, which "dilutes" the difference in hyperemic blood flow between the patients and controls.

Like Rosen et al, we did not find any difference in basal blood flow between the syndrome X patients and the age-matched control group. However, in the group B controls, resting perfusion was lower than that observed in the syndrome X patients. Because the 2 groups were not matched, we did not elaborate on this finding. Compared with the age-matched controls, the important finding is—as explicitly written in our article—reduced coronary blood in patients with syndrome X seems to be caused by a reduction of the increase in blood flow after dipyridamole and not by elevated basal myocardial blood flow.

The ECG changes referred to in our study occurred during exercise testing and not during dipyridamole administration, which rarely causes ECG changes even in severely ischemic patients. Regarding the effect of aminophylline treatment, several newer studies have documented an effect on at least some parameters.R1 R2

We agree with Rosen and Camici that measures other than myocardial perfusion may contribute to the understanding of the severe chest pain symptoms experienced by this patient group. Although the majority of the patients do not show metabolic or functional evidence of myocardial ischemia,R3 R4 R5 {approx}40% have impaired coronary flow reserve.R5 The mechanisms underlying this abnormality are not known, and it was the aim of our study to evaluate this particular point.


*    References 
up arrowTop
up arrowIntroduction
up arrowReferences
up arrowIntroduction 
*References 
 
1. Inobe Y, Kugiyama K, Morita E, et al. Role of adenosine in pathogenesis of syndrome X: assessment with coronary hemodynamic measurements and thallium- 201 myocardial single- photon emission computed tomography. J Am Coll Cardiol. 1996;28:890–896.[Abstract]

2. Elliott PM, Krzyzowska-Dinckinson K, Calvino R, et al. Effect of oral aminophylline in patients with angina and normal coronary arteriograms (cardiac syndrome X). Heart. 1997;77:523–526.[Abstract/Free Full Text]

3. Camici PG, Marraccini P, Lorenzoni R, et al. Coronary hemodynamics and myocardial metabolism in patients with syndrome X: response to pacing stress. J Am Coll Cardiol. 1991;17:1461–1470.[Abstract]

4. Nihoyannopoulos P, Kaski JC, Crake T, et al. Absence of myocardial dysfunction during stress in patients with syndrome X. J Am Coll Cardiol. 1991;18:1463–1470.[Abstract]

5. Bøtker HE, Sonne HS, Bagger JP, et al. Impact of impaired coronary flow reserve and insulin resistance on myocardial energy metabolism in patients with syndrome X. Am J Cardiol. 1997;79:1615–1622.[Medline] [Order article via Infotrieve]





This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosen, S. D.
Right arrow Articles by Czernin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosen, S. D.
Right arrow Articles by Czernin, J.
Related Collections
Right arrow Nuclear cardiology and PET
Right arrow Coronary circulation
Right arrow Endothelium/vascular type/nitric oxide